Behandlung der saisonalen allergischen Rhinokonjunktivitis mit einem liposomalen Nasenspray

Weston, Leslie A.; Mösges, R.

doi:10.5414/alp33196

Cited by 14 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the findings by Böhm et al [6], the safety and tolerability of the treatment investigated here can be assessed as good, since no treatment-related adverse events or serious adverse events occurred. These results are consistent with those from previous studies evaluating the effect of LS for dry eye [8, 10] and with findings from studies assessing liposomal nasal spray [13, 15]. …”

Section: Discussionsupporting

confidence: 83%

“…A previous study assessing a liposomal nasal spray also showed a significant reduction in conjunctival symptoms after its application [15]. This finding shows that a nasal spray is capable of reducing eye symptoms, demonstrating the high efficacy of liposomal products.…”

Section: Discussionsupporting

confidence: 51%

“…Furthermore, results of prospective controlled open studies show that liposomes can be applied as a nasal spray and thus can be successfully used to treat rhinitis symptoms [13-15]: Similar to the effect on the conjunctiva, the liposomes integrate into the destabilized “nasal surfactant” and stabilize the natural moisture film [16]. According to Weston and Mösges [15], the liposomal nasal spray reduced symptoms and significantly improved quality of life in patients with ARC, showing no difference to standard treatment with an antihistamine and/or glucocorticoid spray, as was shown in a prospective, controlled, open, observational study. To assess the efficacy and tolerability in patients with seasonal ARC, Böhm et al [6] compared in a prospective, controlled, open, observational study the use of a liposomal nasal spray in combination with an LS to that of a standard cromoglycate-based combination therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Grzella

Schleicher

Shah‐Hosseini

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Liposomal eye spray (LS) has been introduced for the treatment of dry eye. Whether LS can also relieve symptoms due to allergic rhinoconjunctivitis (ARC) has not yet been sufficiently investigated. Objectives: The aim of this study was to assess the onset of action, the reduction of allergy symptoms, and the safety of LS – a nonpharmacological treatment option – compared with those of antihistamine eye drops (AD). Methods: In this open, prospective, controlled, monocenter noninterventional study, adults with ARC received either LS or AD for the relief of eye irritation after a positive conjunctival provocation test (CPT). All patients completed a questionnaire before and after the CPT. Eye irritation was rated on a visual analogue scale (VAS) at 6 time points. Conjunctival redness was analyzed using objective digital analysis based on images taken during the study visit. Results: Data were collected from 40 patients (20 per group). In both groups, 80% of patients perceived an onset of action within 0–2 min after application of LS or AD following the CPT. Relief of eye irritation (as determined by VAS) increased throughout the visit for both groups. In the digital analysis, the mean proportion of redness of the eye decreased from 10.3 to 7.0% for LS and from 10.4 to 6.5% for AD, with the largest difference observed 10 min after application (LS: 8.9%; AD: 6.0%; p = 0.094). Conclusions: LS is a nonpharmacological treatment option for ARC, showing no significant difference or relevant numerical inferiority to AD in any parameter studied. It was generally safe and well tolerated.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionsupporting

confidence: 51%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Grzella

Schleicher

Shah‐Hosseini

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Such an effect has not been observed in any of the previously conducted studies with LN [14–16] and was caused in all likelihood by the hyperreactive bronchial system, typical in asthma patients and irrespective of application of the specific product.…”

Section: Discussionmentioning

confidence: 76%

“…In earlier studies with the liposomal nasal spray in patients with seasonal allergic rhinitis, a significant reduction in nasal ( p = 0.003) and conjunctivitis ( p = 0.005) symptoms could be achieved and quality of life improved (LN: p = 0.002) [14–16]. Attention was thereby drawn to the possible therapeutic potential in patients with rhinitis sicca.…”

Section: Discussionmentioning

confidence: 99%

Tolerability and effects on quality of life of liposomal nasal spray treatment compared to nasal ointment containing dexpanthenol or isotonic NaCl spray in patients with rhinitis sicca

Hahn

Böhm

Allekotte

et al. 2013

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

This study aimed to investigate symptom reduction via the liposomal nasal spray LipoNasal (LN) in patients with rhinitis sicca. Tolerability and the impact on quality of life were also examined. The same parameters were established in parallel for treatment approaches with Bepanthen (BP) nasal ointment containing dexpanthenol and the Rhinomer (RH) nasal spray containing NaCl. This prospective, controlled, open-label observation study was a multicenter trial. 92 patients with rhinitis sicca were allocated to three arms according to their symptoms: LN: n = 33; BP: n = 32 and RH: n = 27. The study comprised three visits at an interval of 14 days. Efficacy was examined by the Rhinitis Sicca Symptom Score (RSSS) documented daily and at the visits based on an endoscopic evaluation. The nasal spray sensory scale was used to investigate the tolerability. Quality of life (QoL) was measured by means of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and the “Short Form 12” of the “Impact on Health-Related Quality of Life (HRQL)” questionnaire on general quality of life. Nasal symptoms improved significantly (p = 0.001) under all three treatment approaches, reflected by the reduction in the RSSS and the Endoscopy Sum Score. A comparison of the three groups showed that no therapy was significantly superior to any of the others (p = 0.410). The tolerability of all treatments was good. Concerning the nasal moisturization, LipoNasal was evaluated better than Bepanthen and Rhinomer. Quality of life improved in all groups, but not significantly. The results show good efficacy and tolerability of the liposomal nasal spray compared to generally recognized treatments of rhinitis sicca with dexpanthenol nasal ointment and NaCl nasal spray. LipoNasal therefore constitutes a good treatment for patients suffering from dry nose.

show abstract

Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination

Müller‐Goymann

Paranjpe

2016

Pharmaceutical Nanotechnology: Innovation and Production

View full text Add to dashboard Cite

Behandlung der saisonalen allergischen Rhinokonjunktivitis mit einem liposomalen Nasenspray

Cited by 14 publications

References 12 publications

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

Tolerability and effects on quality of life of liposomal nasal spray treatment compared to nasal ointment containing dexpanthenol or isotonic NaCl spray in patients with rhinitis sicca

Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination

Contact Info

Product

Resources

About